NAD+ precursor fact sheet
Nicotinamide mononucleotide
Also known as NMN, beta-NMN
NMN is a biochemical step on the pathway toward NAD+. Early trials report target engagement and scattered functional signals, but not proof of slowed aging or disease prevention.
Quick answer
NMN can affect NAD-related biomarkers in small human trials, but it is not an FDA-approved drug for anti-aging, energy, sleep, muscle performance, or metabolic disease. The clinical significance of reported signals remains uncertain.
Published by PeptideFactSheets. Sources and methods · Research reporting, not clinical review.
What is Nicotinamide mononucleotide?
NMN is a naturally occurring nucleotide derivative used by cells to produce NAD+.
It is related to, but not interchangeable with, nicotinamide riboside or NAD+ itself.
What do the human studies show?
Selected research questions, not a complete inventory of indications or trials. Source checking is not independent clinical review. How we read the evidence.
| Study and people | Question and follow-up | Result and limits |
|---|---|---|
| MIB-626 NMN study Adults aged ≥45 with overweight or obesity 30 participants (actual) Randomized placebo-controlled trial; human | Nicotinamide mononucleotide versus Placebo 28 days Primary: Safety, NAD metabolism and physiological measures; endpoint hierarchy not extracted Phase: Not listed in this summary | Circulating NAD increased; strength, fatigability, aerobic capacity and stair-climbing changes did not differ significantly. Cannot tell us: Multiple short-term outcomes; no inference about lifespan. This formulation cannot represent every NMN product. Safety, uncertainty, and source detailsReported adverse events were similar between groups over 28 days. Limited to the studied population, formulation and follow-up. Funding/conflicts: Not confirmed in this summary; check the full paper. Source checked: 2026-09-18. Independent clinical review: not completed. |
What these results can and cannot tell us
Did the MIB-626 NMN study establish better physical function?
The selected short trial reported target engagement but no significant differences in the listed physical performance measures.
Limit: No conclusion about lifespan, every NMN formulation or every population follows.
Check the sources: MIB-626: NAD augmentation in adults (checked 2026-09-18)
Related, not equivalent: NAD+ · Nicotinamide riboside.
Compare research questions · Submit a source-based correction
Why are people interested in it?
Animal studies made NMN prominent in healthy-aging research, and small human trials have since examined metabolic, walking, sleep, and body-composition endpoints.
Most studies are short, use modest sample sizes, and measure many outcomes, so replication and clinical relevance matter.
Current regulatory status
NMN has no FDA-approved drug indication for aging or any consumer wellness goal. Product-specific U.S. marketing status is a separate legal question from whether a health claim is clinically proven.
What is it approved for?
No approved use is documented by the records summarized here. Commercial availability, supplement marketing, and clinical research do not equal an FDA-approved medicine.
Approval and research context
No FDA-approved drug use
NMN has small human trials and unresolved U.S. product-status questions, but no FDA-approved drug indication for aging, sleep, energy, or metabolic disease.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What is it being studied for?
Evidence snapshot
Human randomized trials are emerging and show biochemical effects, but results for walking, strength, insulin sensitivity, sleep, and other functional outcomes are not yet consistent enough for broad claims.
Potential benefits being researched
- Small trials report increased NAD-related metabolites and some secondary signals in physical function or sleep.
- A controlled trial of a pharmaceutical NMN formulation found target engagement but did not establish a broad physiological rejuvenation effect.
A mechanism, biomarker, or secondary endpoint is not proof of a meaningful clinical benefit.
Known or possible risks
- Short studies cannot rule out uncommon or long-latency harms.
- Commercial products may not match the identity, purity, or stability of material used in a clinical trial.
- The implications of long-term NAD-pathway manipulation in cancer, inflammatory disease, or other conditions are unresolved.
What we still do not know
- Whether any signal replicates in larger and more diverse populations
- Whether changes in biomarkers translate into fewer diseases or better function
- Long-term safety
- Which observed differences reflect NMN rather than chance across many measured endpoints
Plain-English takeaway
NMN is a real research molecule with early human data. It is not yet a proven anti-aging, sleep, metabolic, or performance intervention.
Research and reference links
Use these primary and authoritative sources to verify status and read beyond this summary. A study or registry entry does not by itself prove benefit.
- 1pubmedRandomized NMN trial in older adults
Controlled study of walking, sleep, and related endpoints that requires replication and cautious interpretation.
- 2pubmedRandomized trial of the NMN formulation MIB-626
Human target-engagement and physiological-outcomes trial in adults with overweight or obesity.
- 3pubmedClinical trial of NMN in healthy adults
Small placebo-controlled study assessing short-term safety and selected outcomes.
- 4fdaFDA: what ‘FDA approved’ does and does not mean
FDA explains that dietary supplements are not approved for safety and effectiveness before marketing.